Illumina Asia-Pacific — Total Revenue increased by 13.4% to $93.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 13.4%, from $82.00M to $93.00M. This is a positive signal — higher values indicate stronger performance for this metric.
An increase indicates growing demand for genomic sequencing products and successful expansion in the Asia-Pacific market, while a decrease may signal increased competition, regulatory hurdles, or economic slowdowns in the region.
This metric represents the total revenue generated from sales of sequencing instruments, consumables, and related servic...
Peers in the life sciences and diagnostics sector typically report regional revenue to highlight geographic diversification and exposure to high-growth markets like China and Japan.
ilmn_segment_asia_pacific_total_revenue| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|
| Value | $85.00M | $90.00M | $103.00M | $132.00M | $97.00M | $95.00M | $94.00M | $82.00M | $93.00M |
| QoQ Change | — | +5.9% | +14.4% | +28.2% | -26.5% | -2.1% | -1.1% | -12.8% | +13.4% |
| YoY Change | — | — | — | — | +14.1% | +5.6% | -8.7% | — | +13.4% |